Cancer immunotherapy predictive parameters

Details Cancer immunotherapy predictive parameters Cancer immunotherapy predictive parameters

G - Physics

01

N

G01N 33/50 (2006.01)

Patent

CA 2669994

The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps: - providing a blood sample of said individual, - (a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the number of neutrophils in the blood of said individual, and - (bl) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number Of lymphocytes is below or equal to a lymphocyte baseline level of 1,4 to 1,8 x 109 per liter blood, especially below or equal to 1,6 x 109 per liter blood; or (b2) identifying the individual as having a predictive clinical benefit from the immunotherapy, if the number of neutrophils is below or equal to a neutrophil baseline level of from 4,0 to 6,0 x 109 per liter blood, especially below or equal to 5,0 x 109 neutrophils per liter blood; or (b3) identifying the individual as not having a predictive clinical benefit, if the number of lymphocytes is above a lymphocyte baseline level of 1,4 to 1,8 x 109 per liter blood, especially above 1,6 x 109 per liter blood and the number of neutrophils is above a neutrophil baseline level of from 4,0 to 6,0 x 109 per liter blood, especially above 5,0 x 109 neutrophils per liter blood.

Méthode permettant de prédire l'efficacité d'une immunothérapie anti-cancéreuse chez un individu en termes de bénéfice clinique, englobant les opérations suivantes: dans un échantillon de sang dudit individu, (a1) détermination du nombre de lymphocytes, et/ou (a2) du nombre de neutrophiles; et (b1) identification de l'individu comme susceptible de retirer un bénéfice clinique de l'immunothérapie si le nombre de lymphocytes est inférieur ou égal à un niveau de base de lymphocytes de 1,4 à 1,8 x 109 par litre de sang, en particulier inférieur ou égal à 1,6 x 109; ou (b2) identification de l'individu comme susceptible de retirer un bénéfice clinique de l'immunothérapie si le nombre de neutrophiles est inférieur ou égal à 4,0 à 6,0 x 109 par litre de sang, en particulier inférieur ou égal à 5,0 x 109; ou (b3) identification de l'individu comme non susceptible de retirer un bénéfice clinique de l'immunothérapie si le nombre de lymphocytes est supérieur à un niveau de base de 1,4 à 1,8 x 109 par litre de sang, en particulier supérieur à 1,6 x 109 et si le nombre de neutrophiles est supérieur au niveau de base de 4,0 à 6,0 x 109 par litre de sang,en particulier supérieur à 5,0 x 109.

Affiliated with

Also associated with

Rating

Cancer immunotherapy predictive parameters does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer immunotherapy predictive parameters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy predictive parameters will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1512629